Subscribe

Xvivo Perfusion AB (publ) (XVIVO.ST)

SEK235.20 -20.20 (-7.91%)
SE STO Healthcare Medical - Devices
Address MAessans gata 10 412 51
Gothenburg, SE
CEO Christoffer Rosenblad
IPO 2012-10-08
ISIN SE0004840718

Explore sections of this company profile

Also trades on London Stock Exchange · 0RKL.L (SEK) Other OTC · XVIPF (USD) Other OTC · XVIPY (USD) Stockholm Stock Exchange · XVIVO.ST (SEK)
Description

Xvivo Perfusion AB (publ) is a medical technology company that creates and supplies advanced solutions for the preservation and perfusion of organs, tissues, and cells, primarily for use in transplantation. The company's global reach extends across Sweden, the United States, both North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Its product line includes the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass system designed to facilitate safe normothermic ex vivo lung perfusion (EVLP). To support this, the XPS Disposable Lung Kit offers all the necessary sterile, pre-packed components for EVLP procedures. Xvivo also provides STEEN Solution, an optimally formulated buffered extracellular solution specifically for perfusing isolated donor lungs during EVLP. Additional offerings comprise Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte preservation solution, and the XVIVO Silicone Tubing Set, used for efficient flushing of donor lungs during the procurement process. The company also manufactures the XVIVO LS and XVIVO Disposable Lung Set, both critical devices for EVLP. Furthermore, Xvivo provides the XVIVO Organ Chamber, a sterile, single-use disposable container for temporarily housing isolated lungs before transplantation, and the XVIVO Lung Cannula Set, another sterile, single-use disposable medical product. Established in 1998, Xvivo Perfusion AB (publ) is headquartered in Gothenburg, Sweden.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
SEK235.20 -20.20 (-7.91%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
75.7K
Beta
1.44
Float Shares
25.13M
Free Float %
79.8%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-4.55% -6.86% +0.87% +47.63% +49.22% +52.84% -7.42% -3.05% -12.82% +361.33% +1,356.84%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
235.20
Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 1 0
Buy 3 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
19.29
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • Revenue growth Medical - Devices: +11.2%
    -1.3% Q1'26: +10.2% (vs Q1'25)
  • EPS growth Medical - Devices: +28.5%
    -85.3% Q1'26: +394.9% (vs Q1'25)
  • FCF margin FCF growth · Medical - Devices: +30.9%
    -5.4% Q1'26: +27.1% (vs Q1'25)
  • EBIT margin Medical - Devices: +6.2%
    +10.2% Q1'26: +13.3% (vs Q1'25)
  • ROIC Medical - Devices: +3.3%
    +2.6% Q1'26: +5.5% (vs Q1'25)
  • Share dilution Medical - Devices: 0.0%
    -0.4% Q1'26: -0.3% (vs Q1'25)
  • Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×
    1.55× Q1'26: 0.96× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
WACC components (optional)
Ke (Cost of Equity) = Rf + β (1.42) × ERP
WACC = 97% × Ke + 3% × Kd (18.7%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
Current price: 235.20
Enterprise Value: Equity Value: Terminal Value: TV as % of EV:

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual
Dec 2016
actual
Dec 2017
actual
Dec 2018
actual
Dec 2019
actual
Dec 2020
actual
Dec 2021
actual
Dec 2022
actual
Dec 2023
actual
Dec 2024
actual
Dec 2025
actual
Dec 2026
4 Rev. Ana.
4 EPS Ana.
Dec 2027
4 Rev. Ana.
4 EPS Ana.
Dec 2028
4 Rev. Ana.
4 EPS Ana.
Dec 2029
3 Rev. Ana.
2 EPS Ana.
Dec 2030
3 Rev. Ana.
2 EPS Ana.
Revenue
120.25M
est: 124.84M (-3.7%)
138.18M
est: 141.00M (-2.0%)
148.34M
est: 147.50M (+0.6%)
187.87M
est: 182.33M (+3.0%)
220.84M
est: 222.88M (-0.9%)
179.86M
est: 187.00M (-3.8%)
258.39M
est: 261.30M (-1.1%)
415.29M
est: 400.81M (+3.6%)
597.54M
est: 698.73M (-14.5%)
822.42M
est: 808.16M (+1.8%)
812.17M
est: 800.85M (+1.4%)
1.00B
991.74M – 1.03B
+25.3% YoY
1.33B
1.24B – 1.46B
+32.5% YoY
1.68B
1.67B – 1.68B
+26.1% YoY
2.18B
2.09B – 2.33B
+30.0% YoY
2.85B
2.73B – 3.04B
+30.8% YoY
EBITDA
19.14M
est: 9.88M (+93.7%)
16.21M
est: 11.16M (+45.2%)
22.37M
est: 11.68M (+91.6%)
20.25M
est: 14.43M (+40.3%)
16.81M
est: 17.64M (-4.7%)
-43.33M
est: 14.80M (-392.7%)
39.20M
est: 20.68M (+89.5%)
39.21M
est: 31.73M (+23.6%)
35.05M
est: 115.32M (-69.6%)
272.97M
est: 133.39M (+104.6%)
153.14M
est: 132.18M (+15.9%)
165.57M
163.69M – 169.40M
+25.3% YoY
219.31M
205.21M – 241.71M
+32.5% YoY
276.58M
275.83M – 277.33M
+26.1% YoY
359.57M
344.60M – 384.16M
+30.0% YoY
470.23M
450.65M – 502.38M
+30.8% YoY
EBIT
7.50M
est: 622.2K (+1,105.1%)
3.09M
est: 702.7K (+340.3%)
7.45M
est: 735.1K (+913.7%)
17.63M
est: 908.7K (+1,839.7%)
5.58M
est: 1.11M (+401.9%)
-56.90M
est: 932.0K (-6,205.4%)
6.94M
est: 1.30M (+433.0%)
23.41M
est: 2.00M (+1,071.8%)
4.19M
est: 61.81M (-93.2%)
205.55M
est: 71.49M (+187.5%)
82.93M
est: 70.84M (+17.1%)
88.73M
87.73M – 90.79M
+25.3% YoY
117.53M
109.98M – 129.54M
+32.5% YoY
148.23M
147.83M – 148.63M
+26.1% YoY
192.71M
184.68M – 205.88M
+30.0% YoY
252.01M
241.52M – 269.24M
+30.8% YoY
Net Income
5.13M
est: 13.01M (-60.6%)
1.50M
est: 3.17M (-52.6%)
6.26M
est: 8.49M (-26.3%)
12.69M
est: 18.90M (-32.9%)
4.94M
est: 15.18M (-67.5%)
-43.74M
est: 4.43M (-1,086.5%)
8.15M
est: 8.48M (-3.9%)
18.43M
est: 47.99M (-61.6%)
91.82M
est: 120.74M (-23.9%)
172.18M
est: 162.18M (+6.2%)
25.16M
est: 35.81M (-29.7%)
107.49M
94.38M – 153.18M
+200.2% YoY
209.81M
183.14M – 230.43M
+95.2% YoY
311.22M
288.31M – 381.52M
+48.3% YoY
488.82M
462.36M – 532.27M
+57.1% YoY
792.08M
749.20M – 862.49M
+62.0% YoY
SGA
45.21M
est: 65.22M (-30.7%)
60.20M
est: 73.67M (-18.3%)
63.75M
est: 77.06M (-17.3%)
70.47M
est: 95.26M (-26.0%)
85.53M
est: 116.45M (-26.6%)
90.24M
est: 97.70M (-7.6%)
153.38M
est: 136.53M (+12.3%)
223.38M
est: 209.42M (+6.7%)
309.21M
est: 359.84M (-14.1%)
379.77M
est: 416.20M (-8.8%)
377.09M
est: 412.44M (-8.6%)
516.61M
510.75M – 528.58M
+25.3% YoY
684.30M
640.32M – 754.19M
+32.5% YoY
863.00M
860.66M – 865.34M
+26.1% YoY
1.12B
1.08B – 1.20B
+30.0% YoY
1.47B
1.41B – 1.57B
+30.8% YoY
EPS
0.24
est: 0.41 (-41.6%)
0.07
est: 0.10 (-30.0%)
0.25
est: 0.27 (-6.8%)
0.48
est: 0.60 (-19.6%)
0.19
est: 0.48 (-60.4%)
-1.61
est: 0.14 (-1,250.0%)
0.28
est: 0.27 (+4.5%)
0.62
est: 1.52 (-59.1%)
3.07
est: 3.93 (-21.8%)
5.47
est: 5.05 (+8.3%)
0.80
est: 1.12 (-28.3%)
3.71
2.99 – 4.85
+232.8% YoY
6.77
5.80 – 7.30
+82.4% YoY
10.26
9.14 – 12.09
+51.6% YoY
15.49
14.65 – 16.87
+50.9% YoY
25.10
23.74 – 27.33
+62.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 B- 2/5 1/5 3/5 4/5 3/5 1/5 2/5
2026-05-28 B- 2/5 1/5 3/5 4/5 3/5 1/5 2/5
2026-05-27 B- 2/5 1/5 3/5 4/5 3/5 1/5 2/5
2026-05-26 B- 2/5 1/5 3/5 4/5 3/5 1/5 2/5
2026-05-25 B- 2/5 1/5 3/5 4/5 3/5 1/5 2/5
2026-05-22 B- 2/5 1/5 3/5 4/5 3/5 1/5 2/5
2026-05-21 B- 2/5 1/5 3/5 4/5 3/5 1/5 2/5
2026-05-20 B- 2/5 1/5 3/5 4/5 3/5 1/5 2/5
2026-05-19 B- 2/5 1/5 3/5 4/5 3/5 1/5 2/5
2026-05-18 B- 2/5 1/5 3/5 4/5 3/5 1/5 2/5
2026-05-15 B- 2/5 1/5 3/5 4/5 3/5 1/5 2/5
2026-05-13 B- 2/5 1/5 3/5 4/5 3/5 1/5 2/5
2026-05-12 B- 2/5 1/5 3/5 4/5 3/5 1/5 2/5
2026-05-11 B- 2/5 1/5 3/5 4/5 3/5 1/5 2/5
2026-05-08 B- 2/5 1/5 3/5 4/5 3/5 1/5 2/5
2026-05-07 B- 2/5 1/5 3/5 4/5 3/5 1/5 2/5
2026-05-06 B- 2/5 1/5 3/5 4/5 3/5 1/5 2/5
2026-05-05 C+ 2/5 1/5 2/5 4/5 3/5 1/5 2/5
2026-05-04 C+ 2/5 1/5 2/5 4/5 3/5 1/5 2/5
2026-04-30 C+ 2/5 1/5 2/5 4/5 3/5 1/5 2/5
2026-04-29 C+ 2/5 1/5 2/5 4/5 2/5 1/5 2/5
2026-04-28 C+ 2/5 1/5 2/5 4/5 2/5 1/5 2/5
2026-04-27 C+ 2/5 1/5 2/5 4/5 2/5 1/5 2/5
2026-04-24 C+ 2/5 1/5 2/5 4/5 2/5 1/5 3/5
2026-04-23 C+ 2/5 1/5 2/5 4/5 2/5 1/5 3/5
2026-04-22 C+ 2/5 1/5 2/5 4/5 2/5 1/5 3/5
2026-04-21 C+ 2/5 1/5 2/5 4/5 2/5 1/5 3/5
2026-04-20 C+ 2/5 1/5 2/5 4/5 2/5 1/5 3/5
2026-04-17 C+ 2/5 1/5 2/5 4/5 2/5 1/5 3/5
2026-04-16 C+ 2/5 1/5 2/5 4/5 2/5 1/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
70.56M
OE per share TTM
2.23
Owner's Yield
0.81%
Maintenance CapEx ratio
10.79%
Maint CapEx / Avg PPE
17.5%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
Total invested
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 55 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Global X HealthTech ETF HEAL 0.68% 204.1K 0.50%
2 Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA 0.11% 360.9K 0.23%
3 Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE 0.11% 360.9K 0.23%
4 iShares Healthcare Innovation UCITS ETF HEAL.L 0.09% 977.7K 0.40%
5 iShares MSCI Europe Small-Cap ETF IEUS 0.05% 82.3K 0.41%
6 State Street SPDR S&P International Small Cap ETF GWX 0.05% 408.7K 0.40%
7 Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L 0.05% 1.59M 0.30%
8 iShares $ Treasury Bond 3-7yr UCITS ETF CBUG.DE 0.03% 155.8K 0.10%
9 Schwab International Small-Cap Equity ETF SCHC 0.03% 1.55M 0.06%
10 UBS MSCI World Small Cap Socially Responsible UCITS ETF USD acc WSCSRI.SW 0.03% 231.6K 0.23%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
429.7K
Shares Outstanding
31.50M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Christoffer Rosenblad Chief Executive Officer 6M male
Jaya Tiwari Senior Vice President of Medical Affairs female
Johan Holmstrom Senior Vice President of Commercial Europe & RoW male
Kristoffer Nordstrom CFO and Senior VP of Corporate Strategy & Business Development male
Lena Hagman Chief Operating Officer & Deputy Chief Executive Officer female
Magnus Nilsson Senior Advisor
Mark Reade Senior Vice President of North America male
Ylva Vihoj Senior Vice President of Human Resources female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits